Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 10/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 5/20 | 0.58 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.58 |
| ▸ | HTR1A | P08908 | 3/20 | 0.58 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.58 |
| ▸ | RBP4 | P02753 | 2/20 | 0.53 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.47 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.47 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30228461 | 1.00 | HTR2C (1.00) | HTR2CSLC6A2SLC6A4HTR1ASLC6A3 | |
| Hydrochloric Acid SCHEMBL30853595 | 0.98 | HTR2C (1.00) | HTR2CSLC6A2SLC6A4HTR1ASLC6A3 | |
| Hydrochloric Acid SCHEMBL307161 | 0.98 | HTR2C (1.00) | HTR2CSLC6A2SLC6A4HTR1ASLC6A3 | |
| SCHEMBL2509836 | 0.89 | HTR2C (0.81) | HTR2CSLC6A2SLC6A4HTR1ASLC6A3 | |
| SCHEMBL2509837 | 0.89 | HTR2C (0.81) | HTR2CSLC6A2SLC6A4HTR1ASLC6A3 | |
| SCHEMBL2514720 | 0.89 | HTR2C (0.81) | HTR2CSLC6A2SLC6A4HTR1ASLC6A3 | |
| Hydrochloric Acid SCHEMBL2513159 | 0.88 | HTR2C (0.81) | HTR2CSLC6A2SLC6A4HTR1ASLC6A3 | |
| Hydrochloric Acid SCHEMBL2394649 | 0.88 | HTR2C (0.81) | HTR2CSLC6A2SLC6A4HTR1ASLC6A3 | |
| SCHEMBL5007618 | 0.86 | HTR2C (0.75) | HTR2CRBP4CHRNB2CHRNA4GAA | |
| SCHEMBL2783823 | 0.84 | HTR2C (0.73) | HTR2CSLC6A2SLC6A4HTR1ASLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 99 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260022131-A1 | 4-PHENYLPIPERIDINES, THEIR PREPARATION AND USE | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2026-01-22 | — | — | US | disclosed |
| US-12473302-B2 | 4-phenylpiperidines, their preparation and use | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2025-11-18 | — | — | US | disclosed |
| US-20240287092-A1 | 4-PHENYLPIPERIDINES, THEIR PREPARATION AND USE | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2024-08-29 | — | — | US | disclosed |
| US-11919913-B2 | 4-phenylpiperidines, their preparation and use | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2024-03-05 | — | — | US | disclosed |
| US-11535597-B2 | Photoreactive ligands and uses thereof | THE SCRIPPS RESEARCH INSTITUTE (US) | 2022-12-27 | — | — | US | disclosed |
| US-20210363155-A1 | 4-PHENYLPIPERIDINES, THEIR PREPARATION AND USE | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2021-11-25 | — | — | US | disclosed |
| US-20210363155-A1 | 4-PHENYLPIPERIDINES, THEIR PREPARATION AND USE | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2021-11-25 | — | — | US | disclosed |
| EP-3459948-B1 | FLUORINE-CONTAINING TRIAZOLOPYRIDINE, AND MANUFACTURING METHOD, PHARMACEUTICAL COMPOSITION, AND APPLICATION THEREOF | SHANGHAI INST MATERIA MEDICA CAS (CN) | 2021-11-17 | — | — | EP | disclosed |
| CN-107383002-B | Fluorine-containing triazole pyridine compounds, and preparation method, pharmaceutical composition and application thereof | 中国科学院上海药物研究所 | 2021-07-13 | — | — | CN | disclosed |
| US-11028098-B2 | 4-phenylpiperidines, their preparation and use | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2021-06-08 | — | — | US | disclosed |
| WO-2004113298-A1 | HYDROXAMATE SULFONAMIDES AS CD23 SHEDDING INHIBITORS | CELLTECH R & D LIMITED (GB) | 2004-12-29 | — | — | WO | disclosed |
| US-20040235818-A1 | Aromatic sulfone hydroxamic acid metalloprotease inhibitor | PHARMACIA CORPORATION | 2004-11-25 | — | — | US | disclosed |
| EP-1472244-A1 | AROMATIC SULFONE HYDROXAMIC ACIDS AND THEIR USE AS PROTEASE INHIBITORS | Pharmacia Corporation (US) | 2004-11-03 | — | — | EP | disclosed |
| US-20040209914-A1 | Aromatic sulfone hydroxamic acids and their use as protease inhibitors | PHARMACIA CORPORATION | 2004-10-21 | — | — | US | disclosed |
| US-6750228-B1 | UNCONTROLLED BREAKDOWN OF CONNECTIVE TISSUE BY METALLOPROTEASES IS A FEATURE OF MANY PATHOLOGICAL CONDITIONS | PHARMACIA CORPORATION | 2004-06-15 | — | — | US | disclosed |
| US-6683093-B2 | ENZYME INHIBITORS; CARDIOVASCULAR DISORDERS; ANTIINFLAMMATORY AGENTS; AUTOIMMUNE DISEASE | PHARMACIA CORPORATION | 2004-01-27 | — | — | US | disclosed |
| WO-2003045944-A1 | AROMATIC SULFONE HYDROXAMIC ACIDS AND THEIR USE AS PROTEASE INHIBITORS | PHARMACIA CORPORATION (US) | 2003-06-05 | — | — | WO | disclosed |
| US-20030073718-A1 | Aromatic sulfone hydroxamic acids and their use as protease inhibitors | PHARMACIA CORPORATION | 2003-04-17 | — | — | US | disclosed |
| EP-1183239-A1 | AROMATIC SULFONE HYDROXAMIC ACID METALLOPROTEASE INHIBITOR | G.D. SEARLE & CO. (US) | 2002-03-06 | — | — | EP | disclosed |
| WO-2000069821-A1 | AROMATIC SULFONE HYDROXAMIC ACID METALLOPROTEASE INHIBITOR | G.D. SEARLE & CO. (US) | 2000-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11535597-B2 | Photoreactive ligands and uses thereof | CLTB, CRYAB, CRYAA | HTR2C 2906/4885SLC6A2 3968/4885SLC6A4 3207/4885 |
| US-20240287092-A1 | 4-PHENYLPIPERIDINES, THEIR PREPARATION AND USE | HTR3C, HRH4, DRD3 | HTR2C 25/4885SLC6A2 805/4885SLC6A4 193/4885 |
| US-12473302-B2 | 4-phenylpiperidines, their preparation and use | HTR3C, HRH4, DRD3 | HTR2C 25/4885SLC6A2 805/4885SLC6A4 193/4885 |
| US-11919913-B2 | 4-phenylpiperidines, their preparation and use | HTR3C, HRH4, CYP4F3 | HTR2C 25/4885SLC6A2 786/4885SLC6A4 190/4885 |
| US-20210363155-A1 | 4-PHENYLPIPERIDINES, THEIR PREPARATION AND USE | HTR3C, HRH4, CYP4F3 | HTR2C 25/4885SLC6A2 786/4885SLC6A4 190/4885 |
| US-20040235818-A1 | Aromatic sulfone hydroxamic acid metalloprotease inhibitor | MMP9, MMP13, MMP2 | HTR2C 1698/4885SLC6A2 3721/4885SLC6A4 3160/4885 |
| US-11028098-B2 | 4-phenylpiperidines, their preparation and use | HTR3C, HRH4, CYP4F3 | HTR2C 26/4885SLC6A2 849/4885SLC6A4 213/4885 |
| US-20030073718-A1 | Aromatic sulfone hydroxamic acids and their use as protease inhibitors | MMP1, MMP7, MMP3 | HTR2C 3295/4885SLC6A2 1013/4885SLC6A4 676/4885 |
| US-20040209914-A1 | Aromatic sulfone hydroxamic acids and their use as protease inhibitors | MMP1, MMP7, MMP3 | HTR2C 3295/4885SLC6A2 1013/4885SLC6A4 676/4885 |
| US-20260022131-A1 | 4-PHENYLPIPERIDINES, THEIR PREPARATION AND USE | CLN6, NR2E3, CBR3 | HTR2C 638/4885SLC6A2 1433/4885SLC6A4 1743/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.